Most Recent Articles by Andrea S. Blevins Primeau, PhD, MBA
First-line immune checkpoint inhibition is more cost-effective than chemotherapy for treatment-naïve, BRAF wild-type, stage IV melanoma.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
CLM use during adjuvant endocrine therapy may reduce risk of recurrence in women with early-stage, HR-positive breast cancer.
Acquired reversion mutations in BRCA1/2 are detectable in circulating cell-free DNA (cfDNA) in women with high-grade serous ovarian cancer (HGSC).
Acquired mutations in BTK or PLCG2 were detected in patients with chronic lymphocytic leukemia (CLL) prior to relapse.
More Articles by Andrea S. Blevins Primeau, PhD, MBA
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|